Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases, and their symptoms in Canada, Europe, the United States, Asia, and internationally.
Undervalued with excellent balance sheet.
Share Price & News
How has Crescita Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
Return vs Industry: CTX exceeded the Canadian Pharmaceuticals industry which returned -60.2% over the past year.
Return vs Market: CTX exceeded the Canadian Market which returned 0.9% over the past year.
Price Volatility Vs. Market
How volatile is Crescita Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StThese 4 Measures Indicate That Crescita Therapeutics (TSE:CTX) Is Using Debt Reasonably Well
4 weeks ago | Simply Wall StCrescita Therapeutics (TSE:CTX) Shareholders Have Enjoyed A 94% Share Price Gain
1 month ago | Simply Wall StDo Insiders Own Lots Of Shares In Crescita Therapeutics Inc. (TSE:CTX)?
Is Crescita Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: CTX (CA$0.85) is trading below our estimate of fair value (CA$19.22)
Significantly Undervalued: CTX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CTX is good value based on its PE Ratio (3.1x) compared to the Pharmaceuticals industry average (11.9x).
PE vs Market: CTX is good value based on its PE Ratio (3.1x) compared to the Canadian market (13.6x).
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate CTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CTX is good value based on its PB Ratio (0.8x) compared to the CA Pharmaceuticals industry average (1.9x).
How is Crescita Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Crescita Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Crescita Therapeutics is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Crescita Therapeutics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Crescita Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: CTX's earnings have grown significantly by 36.6% per year over the past 5 years.
Accelerating Growth: CTX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CTX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).
Return on Equity
High ROE: CTX's Return on Equity (26.4%) is considered high.
Return on Assets
ROA vs Industry: CTX has a higher Return on Assets than the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: CTX's Return on Capital Employed has declined over the past 3 years.
How is Crescita Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CTX's short term assets (CA$19.8M) exceeds its short term liabilities (CA$4.8M)
Long Term Liabilities: CTX's short term assets (19.8M) exceeds its long term liabilities (5.0M)
Debt to Equity History and Analysis
Debt Level: CTX's debt to equity ratio (20.5%) is considered satisfactory
Reducing Debt: Insufficient data to determine if CTX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: CTX's debt is well covered by operating cash flow (77.8%).
Interest Coverage: CTX's interest payments on its debt are well covered by EBIT (15.5x coverage).
Inventory Level: CTX has a low level of unsold assets or inventory.
Debt Coverage by Assets: CTX's debt is covered by short term assets (assets are 4.462240x debt).
What is Crescita Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate CTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CTX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if CTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTX's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
What is the CEO of Crescita Therapeutics's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Serge Verreault 0
Mr. Serge Verreault, BA, MBA has been the President of Crescita Therapeutics Inc. since April 17, 2017 and also has been its CEO since April 2, 2018. He served as General Manager of Crescita Therapeutics I ...
CEO Compensation Analysis
Compensation vs. Market: Serge has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Canadian market.
Compensation vs Earnings: Serge's compensation has been consistent with company performance over the past year.
Management Age and Tenure
Experienced Management: CTX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Age and Tenure
Experienced Board: CTX's board of directors are considered experienced (3.3 years average tenure).
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
- Tenure: 0yrs
- Compensation: CA$458.02k
Greg Orleski (63yo)
- Tenure: 2.9yrs
- Compensation: CA$463.71k
President & CEO
- Tenure: 1.5yrs
- Compensation: CA$554.71k
Chief Financial Officer
- Tenure: 1.9yrs
- Compensation: CA$295.52k
Vice President of Business Development
- Tenure: 0yrs
- Compensation: CA$329.40k
- Tenure: 3.6yrs
- Compensation: CA$67.44k
- Tenure: 0yrs
- Compensation: CA$37.44k
- Tenure: 0yrs
- Compensation: CA$458.02k
- Tenure: 3.6yrs
- Compensation: CA$51.44k
- Tenure: 3.1yrs
- Compensation: CA$43.44k
- Tenure: 0.4yrs
Crescita Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Crescita Therapeutics Inc.
- Ticker: CTX
- Exchange: TSX
- Founded: 2016
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$17.834m
- Shares outstanding: 20.98m
- Website: https://www.crescitatherapeutics.com
Number of Employees
- Crescita Therapeutics Inc.
- 2805 Place Louis-R Renaud
- H7V 0A3
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CTX||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Mar 2016|
|CRRT.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Mar 2016|
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases, and their symptoms in ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/16 00:16|
|End of Day Share Price||2019/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.